Ad
related to: Bristol Myers SquibbVisit The Patient Site To Find Important Safety Info, Prescribing Info & Boxed Warnings. Hear From Real Patients About Their Experiences With ELIQUIS® On The Official Site.
- Savings Card
See If You Are Eligible To Save
On An ELIQUIS Prescription
- ELIQUIS & Safety Info
See Full Safety Info &
Boxed Warning. Learn More
- Chat With Elise
Get Help From Our
Virtual Assistant, Elise
- Prescribing Info
See Full Prescribing Info
Including Boxed Warning
- ELIQUIS HCP Info
Visit the Official US Healthcare
Website for ELIQUIS Safety Info
- Doctor Discussion Guide
Learn More About The Interactive
Eliquis Doctor Discussion Guide
- Savings Card
Search results
1-800-721-5072. (toll free U.S. only) As of 2019, Bristol Myers Squibb and Celgene have merged. If you or someone you know have possibly experienced a side effect or have a product complaint while taking a legacy Celgene product, please contact us. 1-800-640-7854.
Bristol Myers Squibb: Creating a Better Future for People with Cancer Bristol Myers Squibb is inspired by a single vision — transforming patients’ lives through science. The goal of the company’s cancer research is to deliver medicines that offer each patient a better, healthier life and to make cure a possibility.
Jun 3, 2022 · About Bristol Myers Squibb. Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.
Bristol Myers Squibb to Present Data at the 2024 American Society of Clinical Psychopharmacology Annual Meeting. 05/22/2024. Bristol Myers Squibb Announces 10-Year Strategy to Reach More Patients in Low- and Middle-Income Countries. 05/21/2024. Bristol Myers Squibb, Taye Diggs and Schizophrenia Community Partner to Empower People with ...
May 27, 2021 · PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Zeposia ® (ozanimod) 0.92 mg for the treatment of adults with moderately to severely active ulcerative colitis (UC), a chronic inflammatory bowel disease (IBD). 1 Zeposia, an oral medication taken once daily, is the first and only sphingosine 1-phosphate ...
It’s through this work that we began writing the next chapter in Bristol Myers Squibb’s 150-year history. Focused on growth. In 2023, we reported $45.0 billion in revenues, GAAP EPS of $3.86 and non-GAAP EPS of $7.51. Our new product portfolio continued to show strength, with its $3.6 billion in revenues representing a 77% year-over-year ...
Help paying for your medicines. If you are a patient in the U.S. struggling to understand your coverage or pay for your medication, we may be able to help. Bristol Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines to patients with serious diseases.
